18hon MSN
MindRank in Phase 3 trial with China’s first AI-assisted new drug, cutting R&D costs by 60%
MindRank announced last month that it had initiated a Phase 3 clinical trial in China for MDR-001, a small molecule GLP-1 receptor agonists designed with the help of AI. GLP-1 rec ...
It’s tempting to order inventory in advance just in case you sell out. But businesses are sitting on $1.40 worth of inventory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback